/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body s response to stress and is essential for survival.
$113.38
+$0.03 (+0.03%)
EOD Sep 1, 2026
Operating margin is thin at 5.88%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 12.8%, still solid. Margins contracted 14.4pp, which offsets some of the top-line progress.
At 270x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 28% versus the prior year, cash generation momentum has weakened.
270.0x earnings, 125.5x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$831M
▲ +12.8% YoY
Net Income (TTM)
$55M
▼ -29.4% YoY
Op. Margin
0.77%
▼ -14.4pp YoY
ROIC
0.76%
▼ -14.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$107M
▼ -27.7% YoY
Op. Cash Flow (TTM)
$110M
▼ -28.4% YoY
Net Debt
-$299M
Net Cash Position
Cash & Equiv.
$308M
5Y CAGR: +16.6%
5Y CAGR: -1.2%
Continue Research
SourceComputed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 30 Jul 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 270.0 and a price-to-free-cash-flow of 125.5, Corcept Therapeutics (CORT) trades above a two-stage DCF intrinsic value of about $18.18 per share, so at $113.38 the stock looks overvalued (84.0% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Corcept Therapeutics scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $18.18 per share for CORT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $13.63. At today's $113.38, that puts the stock about 84.0% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Corcept Therapeutics scores 38 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 0.8% operating margin and a 0.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CORT currently trades above its estimated intrinsic value and scores 38/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.